Regression of Liver Fibrosis Assessed by Transient Elastography After Daclatasvir and Asunaprevir Combined Treatment in Advanced Fibrotic/Cirrhotic Patients With Chronic Hepatitis C Genotype 1b Infection
Not yet recruiting
Phase of Trial: Phase III
Latest Information Update: 09 Mar 2017
At a glance
- Drugs Asunaprevir (Primary) ; Daclatasvir (Primary)
- Indications Hepatic fibrosis; Hepatitis C; Liver cirrhosis
- Focus Therapeutic Use
- Acronyms RELIF-C
- 31 Aug 2016 Planned primary completion date changed from 1 Feb 2021 to 1 Dec 2018.
- 31 Aug 2016 Planned initiation date changed from 1 Oct 2016 to 1 Sep 2016.
- 17 Aug 2016 New trial record